Evidence map›Paper›PMID 22751438›Full record

ArticleCell cycle (Georgetown, Tex.)2012

Cyclin D1 inhibits hepatic lipogenesis via repression of carbohydrate response element binding protein and hepatocyte nuclear factor 4α.

Eric A Hanse, Douglas G Mashek, Jennifer R Becker, Ashley D Solmonson, Lisa K Mullany, Mara T Mashek, Howard C Towle, Anhtung T Chau, Jeffrey H Albrecht

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. DHA Suppresses Hepatic Lipid AccumulationFrontiers in nutrition · 2021
    Article
  12. Article
  13. A negative reciprocal regulatory axis between cyclin D1 and HNF4α modulates cell cycle progression and metabolism in the liver.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  14. Article
  15. Article
  16. The double dealing of cyclin D1.Cell cycle (Georgetown, Tex.) · 2020
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Eric A HanseDivision of Gastroenterology, Hennepin County Medical Center, Minneapolis, MN, USA.
Douglas G Mashek
Jennifer R Becker
Ashley D Solmonson
Lisa K Mullany
Mara T Mashek
Howard C Towle
Anhtung T Chau
Jeffrey H Albrecht
Hennepin County Medical Center · USOrthopaedic Research Foundation · USUniversity of Minnesota System · USMedical Research Foundation · GBMinneapolis Institute of Arts · USUniversity of Minnesota · US

Funding

The Cyclin D1/CDK4 Complex in Hepatocyte ProliferationR01DK054921 · NIDDK · UNIVERSITY OF MINNESOTA · PI ALBRECHT, JEFFREY H · 1998 to 2017
$4.5M
ATGL: Major regulator of hepatic steatosis and energy metabolismR56DK085008 · NIDDK · UNIVERSITY OF MINNESOTA · PI MASHEK, DOUGLAS G · 2010 to 2010
$219k
Novel Functions of D-type Cyclins in HepatocytesF32DK074320 · NIDDK · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCCLENDON, LISA K · 2006 to 2009
$152k
NIDDK NIH HHS DK085008NIDDK NIH HHS DK54921NIDDK NIH HHS F32 DK074320NIDDK NIH HHS F32DK074320NIDDK NIH HHS R01 DK054921NIDDK NIH HHS R56 DK085008
6 · The paper itself

Abstract

Following acute hepatic injury, the metabolic capacity of the liver is altered during the process of compensatory hepatocyte proliferation by undefined mechanisms. In this study, we examined the regulation of de novo lipogenesis by cyclin D1, a key mediator of hepatocyte cell cycle progression. In primary hepatocytes, cyclin D1 significantly impaired lipogenesis in response to glucose stimulation. Cyclin D1 inhibited the glucose-mediated induction of key lipogenic genes, and similar effects were seen using a mutant (D1-KE) that does not activate cdk4 or induce cell cycle progression. Cyclin D1 (but not D1-KE) inhibited the activity of the carbohydrate response element-binding protein (ChREBP) by regulating the glucose-sensing motif of this transcription factor. Because changes in ChREBP activity could not fully explain the effect of cyclin D1, we examined hepatocyte nuclear factor 4α (HNF4α), which regulates numerous differentiated functions in the liver including lipid metabolism. We found that both cyclins D1 and D1-KE bound to HNF4α and significantly inhibited its recruitment to the promoter region of lipogenic genes in hepatocytes. Conversely, knockdown of cyclin D1 in the AML12 hepatocyte cell line promoted HNF4α activity and lipogenesis. In mouse liver, HNF4α bound to a central domain of cyclin D1 involved in transcriptional repression. Cyclin D1 inhibited lipogenic gene expression in the liver following carbohydrate feeding. Similar findings were observed in the setting of physiologic cyclin D1 expression in the regenerating liver. In conclusion, these studies demonstrate that cyclin D1 represses ChREBP and HNF4α function in hepatocytes via Cdk4-dependent and -independent mechanisms. These findings provide a direct link between the cell cycle machinery and the transcriptional control of metabolic function of the liver.

Indexed as

AnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCells, CulturedCyclin D1Cyclin-Dependent Kinase 4Gene Expression RegulationGlucoseHepatocyte Nuclear Factor 4HepatocytesLipid MetabolismLipogenesisMiceNuclear ProteinsProtein BindingProtein Structure, TertiaryRNA InterferenceBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCyclin D1Cyclin-Dependent Kinase 4GlucoseHepatocyte Nuclear Factor 4Mlxipl protein, mouseNuclear ProteinsRNA, Small InterferingTranscription Factors

Identifiers

PMID22751438
PMCPMC3409010
OpenAlexW2055568030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.